Company Overview and News

 
Combatting bank scams and frauds

2018-09-21 bworldonline
Scams and frauds remain a serious threat to financial institutions and consumers, especially these days when fraudsters are becoming more sophisticated as the technologies and methods they employ advance over time. Innovations that allow people to conveniently manage financial tasks and transactions via digital channels have ironically opened opportunities for fraudsters to deceive the banking public.
BPI

 
BPI raises $600 million through fixed-rate notes

2018-08-29 bworldonline
Bank of the Philippine Islands (BPI) raised $600 million through a senior unsecured note drawdown to maximize flexibility in offshore funding and diversify its liquidity sources.
BPI

 
BPI Direct BanKo aims to hit goal of opening 200 branches this year

2018-08-13 bworldonline
BPI Direct BanKo Inc., the microfinance unit of Bank of the Philippine Islands (BPI), is set to hit its target of having 200 branches by year-end, leveraging on the branch-lite initiative of the local central bank.
BPI

4
BPI MTN gets Baa2 rating

2018-06-25 bworldonline
MOODY’S Investors Service has assigned an investment grade rating on the $2-billion medium-term note (MTN) facility of Bank of the Philippine Islands (BPI).
BPI DB

 
Moody’s assigns investment grade to BPI’s $2-billion note program

2018-06-25 bworldonline
Moody’s Investors Service has assigned an investment grade to the $2-billion medium-term note (MTN) facility of Bank of the Philippine Islands (BPI).
BPI

10
BPI to offer up to $2-B medium term notes

2018-06-22 bworldonline
BANK of the Philippine Islands (BPI) said it has been authorized by its board to establish an up to $2 billion dollar-denominated medium-term note (MTN) program, with the notes to be listed in Singapore.
BPI DB PNB RZLLY RCB

4
BPI sets up MTN program to raise up to $2 billion

2018-06-22 bworldonline
Bank of the Philippine Islands (BPI) has established a dollar-denominated medium-term note (MTN) program to maximize flexibility in raising capital.
BPI DB

 
What’s in a name?

2018-06-19 bworldonline
AN ONGOING exhibition at the Ayala Museum called Historia showcases 54 artworks that span the history of the Bank of the Philippine Islands (BPI) from 1851 when BPI was still called Banco Español Filipino de Isabel II to today’s modern art in keeping with today’s modern bank.
BPI

 
BPI still studying use of blockchain technology

2018-05-13 bworldonline
BANK OF THE Philippine Islands (BPI) is not yet keen on using blockchain technology as the lender is still studying the applicability to banking processes.
BPI BPHLY BPHLF

 
BPI net income flat in Q1

2018-05-07 bworldonline
BANK OF THE Philippine Islands (BPI) saw steady income in the first quarter despite improved revenues due to higher expenses and lower trading gains.
BPI BPHLY BPHLF

 
BPI profit flat in first quarter

2018-05-07 bworldonline
Bank of the Philippine Islands (BPI) posted flat income in the first quarter despite logging revenue growth.
BPI

4
BPI lists SRO shares

2018-05-04 bworldonline
BANK OF THE Philippine Islands (BPI) has listed 599.7 million new common shares at the local bourse following the completion of a P50-billion stock rights offer.
BPI DB BPHLY BPHLF

3
BPI lists new shares worth P53.67 billion

2018-05-04 bworldonline
Bank of the Philippine Islands (BPI) has listed 599.7 million new common shares at the local bourse following the completion of a P50-billion stock rights offer.
BPI PSE

9
BPI raises P50 billion from stock rights offering

2018-05-03 bworldonline
BANK OF THE Philippine Islands (BPI) has completed its stock rights offer (SRO), raising P50 billion to fund its business operations and expansion.
BPI DB PSKXF PHSXY PSE BPHLY BPHLF

 
BPI raises P50 billion from stock rights offer

2018-05-03 bworldonline
Bank of the Philippine Islands (BPI) has completed its stock rights offer (SRO), raising P50 billion to fund its business operations and expansion.
BPI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:BPI / Bank of the Philippine Islands on message board site Silicon Investor.

BPI Industries Ltd (BPR-VSE) BPI Industries Ltd (BPR-VSE) BPI Industries Ltd (BPR-VSE) LBPI: LBP, Inc. LBPI: LBP, Inc. LBPI: LBP, Inc.
BPI, Big Picture Technologies BPI, Big Picture Technologies BPI, Big Picture Technologies IBPI: IntraBiotics Pharmaceut. IBPI: IntraBiotics Pharmaceut. IBPI: IntraBiotics Pharmaceut.
BPI Financial BPI Financial BPI Financial Basic Petroleum BPILF Guatamalan Pipeline Basic Petroleum BPILF Guatamalan Pipeline Basic Petroleum BPILF Guatamalan Pipeline